Investing in biotechnology stocks is complex due to the science behind the company’s drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.
However, biotech stocks offer a compelling risk-rewa.... |
Good MorningThe Federal Reserve’s quarter-point rate cut and signal of two more reductions this year sent Treasury yields lower and kept equities near record highs. The Dow rose 0.6%, while the S&P 500 and Nasdaq slipped slightly as investors weighed the dovish shift against growth concerns. Defensive stocks outperformed tech late in the session.
Tech and AI leaders remained in focus after upgrades highlighted strength in AI names, with NVIDIA leading momentum despite China export curbs. Meta is unveiling AI-powered glasses, and Amazon pledged $1 billion to boost wages and cut healthcare costs. Meanwhile, StubHub’s IPO fell 6% below its $23.50 debut price, underscoring mixed market sentiment. Featured: This Single Fund Owns Every Major AI Stock and Pays Weekly (Ad) 
| Healthcare | |
Investing in biotechnology stocks is complex due to the science behind the company’s drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.
However, biotech stocks offer a compelling risk-rewa... Read the Full Story |
| From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
| Industrials | |
A recent Buy upgrade from Melius Research has sharpened investor focus on GE Vernova (NYSE: GEV), accompanied by a new, optimistic $740 price target. This signal from Wall Street is underpinned by a powerful catalyst transforming the energy sector: the explosive growth of artificial intelligence... Read the Full Story |
| Technology | |
Macro is often an intimidating term for retail investors, as it encompasses everything from interest rates to inflation, employment, and global capital flows. However, macroeconomic forces are the true drivers behind every major market cycle.
Not Federal Reserve (the Fed) rate cuts or hikes, not ... Read the Full Story |
| From Our Partners | | Tobacco, telecom, pipelines, and healthcare real estate trade at 10 to 15 times earnings while the index yields about 1 percent.
A free report highlights seven cash-generating stocks with a 5 percent forward yield floor and roughly 6.5 percent average cash yield, capped at two picks per sector.
Each pick includes coverage numbers and an honest bear case. Five of the seven have raised payouts for 17 to 56 straight years. | | Get the seven high-yield dividend stocks free now |
| Consumer Discretionary | |
Dave & Buster’s (NASDAQ: PLAY) FQ2 earnings report was no blowout with tepid revenue growth and a significant contraction in earnings.
However, it still highlights the company’s strengths and the significant potential for recovery, which has greatly improved. The company found i... Read the Full Story |
| Consumer Discretionary | |
Retail giant Nike Inc. (NYSE: NKE) and its stock have to be one of the industry's horror stories from recent years. After soaring through the pandemic, shares have since fallen in a near-continuous slide that's wiped out more than 60% of their value, while the major indices have been printing re... Read the Full Story |
| From Our Partners | | AI is expanding beyond software into robots, factories, vehicles, and intelligent machines. That shift could create a new group of market leaders before most investors notice.
A complimentary report, 5 Stocks Powering the Physical AI Revolution, identifies five companies positioned at the center of this shift, along with the technologies, growth drivers, and risks to understand. | | Get your free copy before physical AI becomes Wall Street's next crowded trade |
| Communication Services | |
Tech giant Oracle (NYSE: ORCL) recently put out an earnings report that left many market observers in awe. The company’s Q1 fiscal 2026 sales and adjusted earnings per share weren’t what impressed; Oracle actually missed estimates on both figures. However, Oracle’s outlook was ... Read the Full Story |
| Technology | |
Less than a week after providing a highly encouraging financial update that sent shares soaring, chip giant Broadcom (NASDAQ: AVGO) made another huge move.
On Sept. 10, shares surged by approximately 9.8%, eclipsing the 9.4% up-move seen after Broadcom’s Sept. 4 earnings report.
This all... Read the Full Story |
| Technology | |
The changes to MarketBeat’s screen for Most Upgraded Stocks posted since the FQ2 earnings reports were released are significant. These are perhaps the most critical changes in many quarters, as the AI market leaders are back in the analysts’ favor.
Stocks in the ranking include five o... Read the Full Story |
| Technology | |
A landmark $6.3 billion deal with AI chip leader NVIDIA (NASDAQ: NVDA) recently sent shares of CoreWeave (NASDAQ: CRWV) soaring, crystallizing the company’s crucial role in the artificial intelligence (AI) boom. The market’s excitement reflects a growing understanding of a classic in... Read the Full Story |
| Technology | |
CrowdStrike Holdings Inc. (NASDAQ: CRWD) is in a quiet period of sorts. The company won’t report earnings until the end of November, meaning investors have to get through what are notoriously sluggish months for stocks with no fuel beyond headline news to push CRWD stock higher.
Fortunate... Read the Full Story |
| Thursday's Early Bird Stock Of The Day argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. | Should I Buy argenex Stock? ARGX Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of argenex was last updated on Monday, October 12, 2026 at 7:27 PM.
argenex Bull Case -
argenx SE successfully met the primary endpoint in its Phase II celiac disease study for its candidate drug FB102, a development that paves the way for late-stage development and provides a new growth driver for the company's pipeline.
-
The company demonstrated strong financial performance in its most recent quarterly report, beating consensus estimates with an earnings per share of $7.32 compared to the expected $5.86, while also exceeding revenue forecasts with $1.54 billion in sales against an estimate of $1.45 billion.
-
argenx SE maintains a favorable valuation profile with a P/E/G ratio of 0.86, which suggests that its growth rate is high relative to its current price-to-earnings multiple, potentially offering attractive value to growth-oriented investors.
-
With the current stock price at $812.30, the shares are trading significantly below the consensus price target of $1,158.61, indicating that analysts believe there is substantial upside potential remaining in the stock.
-
The company's lead product, efgartigimod, continues to drive revenue as a therapy for severe autoimmune diseases, supported by a robust commercial infrastructure and a strong market position in the immunology sector.
argenex Bear Case -
argenx SE recently discontinued its late-stage Phase 3 trial for Vyvgart in Sjögren's disease due to a futility finding, a significant setback that caused the stock to tumble nearly 15% and raises concerns about the company's ability to expand its lead product into new indications.
-
Several major financial institutions have recently lowered their price targets for the stock, including Oppenheimer cutting its target to $1,038.00 and Robert W. Baird reducing its target to $823.00, reflecting a more cautious outlook on the company's near-term prospects.
-
The stock has experienced significant volatility, including a gap down of $97.21 on October 8, 2026, which highlights the high risk associated with the company's pipeline developments and market sentiment.
-
Legal risks are increasing as SBS Law and SueWallSt have notified investors of pending fraud investigations into argenx SE, which could lead to costly litigation and further damage to the company's reputation.
-
Short interest in the stock has been rising, with shares shorted increasing to 1,352,184 as of September 30, 2026, indicating that a growing number of investors are betting against the company's future performance.
| | View Today's Stock Pick |
|
| |
|
|
